A detailed history of Peregrine Capital Management LLC transactions in Insmed Inc stock. As of the latest transaction made, Peregrine Capital Management LLC holds 172,837 shares of INSM stock, worth $12.8 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
172,837
Previous 179,932 3.94%
Holding current value
$12.8 Million
Previous $12.1 Million 4.66%
% of portfolio
0.4%
Previous 0.36%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$62.0 - $79.01 $439,890 - $560,575
-7,095 Reduced 3.94%
172,837 $12.6 Million
Q2 2024

Jul 29, 2024

SELL
$22.0 - $69.71 $2.43 Million - $7.68 Million
-110,242 Reduced 37.99%
179,932 $12.1 Million
Q1 2024

Apr 26, 2024

BUY
$25.72 - $29.94 $2,211 - $2,574
86 Added 0.03%
290,174 $7.87 Million
Q4 2023

Jan 26, 2024

SELL
$23.42 - $31.74 $1.17 Million - $1.59 Million
-50,037 Reduced 14.71%
290,088 $8.99 Million
Q3 2023

Oct 19, 2023

SELL
$19.86 - $26.93 $424,924 - $576,194
-21,396 Reduced 5.92%
340,125 $8.59 Million
Q2 2023

Jul 26, 2023

SELL
$16.44 - $21.1 $2,071 - $2,658
-126 Reduced 0.03%
361,521 $7.63 Million
Q1 2023

Apr 26, 2023

BUY
$16.26 - $21.73 $173,624 - $232,032
10,678 Added 3.04%
361,647 $6.17 Million
Q4 2022

Jan 10, 2023

SELL
$16.98 - $23.15 $180,565 - $246,177
-10,634 Reduced 2.94%
350,969 $7.01 Million
Q3 2022

Oct 26, 2022

BUY
$20.88 - $28.21 $666,385 - $900,322
31,915 Added 9.68%
361,603 $7.79 Million
Q2 2022

Jul 20, 2022

SELL
$17.07 - $25.71 $4,677 - $7,044
-274 Reduced 0.08%
329,688 $6.5 Million
Q1 2022

Apr 27, 2022

SELL
$20.42 - $28.13 $483,239 - $665,696
-23,665 Reduced 6.69%
329,962 $7.75 Million
Q4 2021

Jan 31, 2022

BUY
$25.89 - $33.45 $258,330 - $333,764
9,978 Added 2.9%
353,627 $9.63 Million
Q3 2021

Nov 02, 2021

BUY
$22.46 - $29.47 $7.72 Million - $10.1 Million
343,649 New
343,649 $9.46 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Peregrine Capital Management LLC Portfolio

Follow Peregrine Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.